Characterizing wheeze phenotypes to identify endotypes of childhood asthma, and the implications for future management by Belgrave, DC et al.
1 
 
Characterising wheeze phenotypes to 
identify endotypes of childhood 
asthma, and the implications for future 
management  
Danielle C. M. Belgrave MSc1,2, Adnan Custovic MD PhD1 and Angela Simpson MD PhD1 
1Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of 
Manchester and University Hospital of South Manchester, Manchester, UK 
2Centre for Health Informatics, Institute of Population Health, University of Manchester, UK 
  
2 
 
Abstract 
It is now a commonly held view that asthma is not a single disease, but rather a set of 
heterogeneous diseases sharing common symptoms. One of the major challenges to treating asthma 
is understanding these different asthma phenotypes and their underlying biological mechanisms. 
This review gives an epidemiological perspective of our current understanding of the different 
phenotypes that develop from birth to childhood that come under the umbrella term “asthma”.  The 
review focuses mainly on publications from longitudinal birth cohort studies where the natural 
history of asthma symptoms is observed over time in the whole population.  Identifying distinct 
pathophysiological mechanisms for these different phenotypes will potentially elucidate different 
asthma endotypes, ultimately leading to more effective treatment and management strategies. 
Keywords: asthma phenotypes, endotypes, epidemiology, machine learning, longitudinal cohorts 
Introduction 
The increasing global prevalence of childhood asthma is of major concern[1]. One of the challenges 
to understanding the pathophysiology and aetiology of this disease is the lack of consensus in 
defining asthma in the medical literature. A recent systematic review showed that in 122 
publications investigating risk factors associated with childhood asthma, 60 different definitions 
were used[2]. Although many of these definitions were similar (with apparently subtle differences 
between them), the impact of this heterogeneity on the reported results and our understanding of 
asthma is unclear. When four of the most commonly used definitions were applied to a high risk 
population of 186 children, the overall agreement was 61%, indicating that 39% of the children could 
move from ‘asthma’ to ‘not asthma’ depending on which definition was used[2]. Such variability will 
obviously affect the performance of prediction models. It is clear that better tools for the diagnosis 
of asthma are required, both for clinical practice and for epidemiological studies. Throughout the 
remainder of this review, we will present evidence to support our view that “asthma” is not a single 
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disease but rather represents an umbrella term used to describe a collection of heterogeneous 
diseases presenting with similar symptoms[3] such as recurrent episodes of wheeze, cough, 
breathlessness and chest tightness[4]. We will also explain the importance of identifying and 
describing these separate entities. For many of our patients, asthma starts early in life, therefore we 
have focused this review on paediatric studies, in particular birth cohorts. For many others asthma 
starts in adulthood, and although this can be severe and is certainly heterogeneous, a summary of 
that literature is beyond the scope of the current review. 
Asthma runs in families and is clearly heritable, but patterns of inheritance are complex and genetic 
studies have shown poor replication, and loci which have been replicated generally explain a very 
small proportion of the heritability, with small effect sizes[5,6]. The rapid increase in the prevalence 
of asthma seen in the later part of the last century strongly indicates that environmental exposures 
are highly relevant in the aetiology of wheezing illnesses. Despite several decades of extensive 
epidemiological study, we are still unable to explain the increase in prevalence, and findings are 
inconsistent for most environmental factors. An example of an inconsistent association with asthma 
is day-care attendance. Different studies have indicated that day-care attendance increases the 
risk[7], is protective[8] and has no effect[9] on the development of asthma. It is likely that imprecise 
phenotype definition together with the failure to take account of interactions between the 
environment and genetic predispositions (day care - TLR2, endotoxin - CD14 being but two 
examples) [10-12] have hampered our attempts to ‘explain’ asthma. In order to progress our field of 
knowledge, and to design targeted and effective treatments for our wheezing patients, we need to 
precisely define the diseases under the “asthma umbrella”, and then determine their genetic and 
environmental predictors. Whereas phenotype is indicative of the observable characteristics or 
symptoms of a disease, an endotype refers to “a subtype of a condition, which is defined by a 
distinct functional or pathophysiological mechanism”[13]. Disentangling the different phenotypes 
that are generically described as “asthma” is an important step towards describing true endotypes of 
asthma with distinct underlying pathophysiological mechanisms[13]. Defining  distinct endotypes of 
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asthma  (which may have different causes) will facilitate more precise treatment and management 
strategies for these different diseases. 
Although wheeze is the most commonly observed manifestation of asthma, it has long been 
recognised that all that wheezes is not asthma, particularly in pre-school age, and that distinctions 
are important in terms of therapeutics[14]. Furthermore, sequential cross-sectional studies of 
populations of children from school age will never allow a description of the within individual natural 
history of wheezing illness. The existence of longitudinal observational birth cohorts which record 
the natural history of asthma-related symptoms over time such as wheeze and cough  have allowed 
us to describe patterns in the rich and complex datasets, to classify children based on the frequency 
and severity of symptom progression from birth through early childhood.[15-18] Understanding the 
heterogeneity or different manifest patterns of wheeze over time (wheeze phenotypes), may help us 
to differentiate different phenotypes which present under the umbrella term of “asthma” (asthma 
phenotypes) whilst acknowledging that not all phenotypes of asthma have wheeze as the dominant 
symptom (for example cough-variant asthma).  Causative factors of recurrent wheeze may vary from 
child to child, and within a child over time due to a large number of interactions between genetic 
and environmental factors.[19,20]  By identifying homogenous groups of children with similar 
disease features, we hope to better understand the development, comorbidities and associated 
genetic and environmental risk factors for these entities. Ultimately, this will have major implications 
for the effective treatment, prevention and management of this disease which is of increasing global 
concern[21]. 
Towards a Definition of the Asthma Phenotype 
We can divide the approaches to classifying children according to distinct asthma phenotypes as 1) a 
subjective hypothesis-driven approach whereby the investigator looks at individual changes in the 
profile of asthma symptoms throughout childhood and then classifies children into different 
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phenotypes based on common patterns of symptoms over time and 2) a data-driven or hypothesis-
generating approach, whereby the investigator uses latent variable modelling techniques. 
Hierarchical clustering is a latent variable modelling technique which allows us to infer that we can 
partition homogeneous groups of patients into meaningful clusters. It is assumed that different 
clusters have different probability distributions and patients with similar probability distributions 
form a cluster. Hierarchical clustering can be used to classify profiles of symptoms over time which 
are continuous (such as lung function) or a mixture of continuous and categorical data. Latent class 
analysis (LCA) is a type of hierarchical clustering which is used when we have categorical data or a 
binary diagnosis (i.e. symptom present or symptom absent). This is especially useful where we have 
multiple dichotomous symptoms, such as wheeze, which is tracked over time. LCA is a statistical 
method used when we infer that some latent generalisation or hypothetical construct, exhibits 
certain observable characteristics. This approach is widely applied in the clinical psychiatry literature 
[22-26] where investigators try to measure the severity of conditions which are not directly observed 
such as depression, intelligence or schizophrenia. These conditions are not directly measurable, but 
rather severity can be represented using a set of discrete latent constructs which can be derived 
based on a series of observable disease manifestations. In the same way, we can think of different 
childhood asthma phenotypes as latent states whose existence is made manifest by the longitudinal 
pattern of wheeze and/or other respiratory symptoms over time. We assume that each child belongs 
to one of N latent classes, where the number and size of these latent classes is unknown. Different 
assumptions of the number of classes, N, are investigated in the model and the models are 
compared for goodness-of-fit to select the optimal number of latent profiles which best describe the 
observed heterogeneity in asthma symptoms between children over time. These probability-based 
modelling techniques gives us an objective method of assigning children to different latent asthma 
phenotypes with a robust evaluation of model reproducibility.  
Within the literature, the most common approach used for identifying phenotypes of childhood 
asthma is to look at the natural history of wheeze over time, since this is the most easily measurable 
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symptom of asthma. This mimics the real-life scenario whereby a history of recurrent wheeze is very 
often used to make a clinical asthma diagnosis. Although many other symptoms are related to 
asthma such as cough, shortness of breath and chest tightness  there has been lack of reproducibility 
and consensus in identifying the best subgroup of symptoms to identify asthma phenotypes. This 
further justifies the use of recurrent wheeze which is by clinical consensus the most common 
manifestation of asthma. Therefore, this review focuses mainly on understanding wheeze 
phenotypes by looking for heterogeneous patterns of wheeze over time. Such an approach helps us 
to disambiguate the complex patterns of childhood wheeze.  
Subjective Approaches to Defining Wheeze Phenotypes 
Martinez et al in the Tucson Children Respiratory Study (TCRS) presented the first longitudinal 
classification of children into distinct wheeze phenotypes, based on the clinical assessment of the 
natural history of wheeze in the first six years of life. Based on these longitudinal patterns in 826 
children, the authors assigned each child to one of four categories according to their history of 
wheezing: (1) children who never wheezed (51%), (2) transient early wheezing: these children 
presented with recurring wheeze till age three years, but grew out of wheeze by age six years (20%),  
(3) late-onset wheezing: these children did not wheeze in the first three years of life and then 
presented with wheeze at age six years (15%) and (4) persistent wheezing: these children had an 
onset of wheeze in early life which persisted to age six years (14%).[27] This classification identified 
that more than half of infant wheezing was transient, associated with diminished airway function in 
infancy, and was not associated with risk of asthma or allergies in later childhood.  A number of birth 
cohorts have used similar approaches of investigator-imposed classifications to define and 
investigate clinical associations of different wheeze phenotypes[28]. This has led to the description 
of phenotypes of wheeze with similar names but differing definitions, making comparisons across 
cohorts challenging.[4,29-33] 
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Hypothesis-generating Approaches to Defining Phenotypes Based on Presence or Absence of Wheeze 
across Time 
The Avon Longitudinal Study of Parents and Children (ALSPAC), was the first study to consider the 
use of a probabilistic data-driven approach to classify children into different wheeze phenotypes. 
This study used latent class analysis to assign 6265 children to different phenotypes based on the 
longitudinal patterns of wheezing within the first seven years of life. They identified an optimal 
modelling solution of six phenotypes based on model goodness-of-fit statistics. By observing the 
prototypical pattern of wheeze over time for each class, the investigators labelled them as: (1) 
Never/infrequent wheeze (59%) (2) intermediate onset wheeze (3%): children who had no wheeze in 
the first year of life, but had an increasing probability of wheeze from ages two and a half years to 
age seven (3) transient early wheeze: children who wheezed in the first two and a half years of life, 
but grew out of wheeze between ages three and four years (16%) (4) prolonged early wheeze: 
children who grew out of wheeze by age six years (9%) (5) late onset wheeze: children who had a low 
probability of wheeze in the first three years of life, with increasing probability of wheeze between 
ages four and seven years (6%) and (6) children with persistent wheeze who had a high probability of 
wheeze throughout childhood (7%).[34] This data-driven approach with a larger study sample 
identified  the three wheezing phenotypes described using the TCRS data, but detected two novel 
wheeze classes (intermediate and prolonged early). 
An important validation of this data-driven approach to defining wheeze phenotypes has been the 
replication of these findings in the Dutch Prevention and Incidence of Asthma and Mite Allergy 
(PIAMA) cohort.[35] This study which has similar data-collection points to ALSPAC found evidence of 
the novel intermediate-onset wheeze phenotype. Phenotypes identified had similar clinical 
characteristics to ALSPAC and the probability of membership to the different wheeze classes was 
also similar. However, the optimal model was a five-latent-class solution which did not identify the 
prolonged early wheeze phenotype. In a later study, it was hypothesised that since prolonged early 
and transient early have very similar characteristics and risk factors, prolonged early wheeze may be 
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a more severe form of transient early wheeze.[36] By using an objective data-driven approach across 
two geographically distinct cohorts, the investigators were able to derive broadly similar latent 
classes of wheeze with similar associations.  
Chen et al[37] used similar latent modelling techniques to identify phenotypes of 689 children from 
the Columbia Center for Children’s Environmental Health study (CCCEH) age 3 to 108 months using 
more complex assumptions of changes in the natural history of wheeze over time. They identified 
four classes of children, (never/infrequent, early transient, early persistent and late onset) similar to 
the TRCS study. 
One of the problems with identifying wheeze phenotypes in longitudinal birth cohorts is that 
presence of wheeze is often based on parental reporting of wheeze. We have previously  shown that 
a high proportion (approximately one third) of parentally reported wheeze was not confirmed on 
physician consultation[38]. The confirmation of wheeze by a doctor may give a more accurate 
judgment on the presence (and severity) of wheeze. Incorporating information on wheeze from both 
parental and clinical sources can elucidate both dimensions of uncertainty and severity of the 
asthma endotype. Both sources provide important information and are complimentary - it is 
recognised that parents may misdiagnose wheeze, so the physician report is an important 
confirmation in early life[38]; conversely treatment may suppress wheeze leading to underreporting 
of events by parents. A further complicating factor is that parents may not always consult a primary 
care physician for non-severe wheeze events. Using longitudinal latent class modeling[39] of 
questionnaire data completed by parents and the data transcribed from primary care medical 
records on wheeze within the first eight years of life, we have recently investigated longitudinal 
patterns of wheezing amongst children in the Manchester Asthma and Allergy Study (MAAS)[40]. 
This approach of joint modelling of ‘higher resolution’ data pertaining to wheeze events, allowed us 
to model uncertainty in parental or physician diagnosis of wheeze.  We identified four classes of 
wheeze (in addition to a non-wheezing class)[40]. Based on our interpretation of their 
characteristics, we named two of the classes transient early-wheeze, and late onset wheeze, similar 
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to TCRS. However, our model identified two classes of children with persistent wheeze, and based 
on their consulting behaviour and requirements for asthma treatment, we named them Persistent 
troublesome and Persistent controlled wheeze[40]. So, how similar are the findings between 
different methods and different cohorts? Using data collected for in the Southampton’s Women’s 
Survey (SWS) from 1973 children (born to >12,000 women recruited pre-conception) and followed 
prospectively (including infant lung function in 150), researchers have assigned children to the TCRS 
classes and also to the ALSPAC classes[41]. They concluded that a six class (ALSPAC) model better 
reflected their data. We have compared the proportion of children in each class when the TCRS 
phenotypes are applied (Tables 1 A and B) and also the proportions assigned to each class for data 
driven approaches (Table 2 A and B). All cohorts, whether using objective or subjective classification 
methods identified the four common classes: No Wheeze, Transient-early Onset, Late-onset wheeze 
and Persistent Wheeze. However the proportion of children assigned to each class varies by cohort. 
There is up to 10-fold variation in the proportion of wheezing children who are assigned to late 
onset wheeze defined according to TCRS criteria (Table 1B), but a similar variability  in the size of the 
late onset class is seen when data driven approaches are applied (Table 2B). Although this may in 
part reflect the time points at which data was collected and the differing characteristics of the 
cohorts, it does indicate that further work is required before the definitive phenotypes are 
identified.  
 
Table 1: Summary of wheeze phenotypes identified in some birth cohorts with proportion of 
children assigned to each class using the TCRS classification for A) the whole population, and 
B) the proportions amongst wheezing children. 
 
Table 1A 
Phenotypes Identified TCRS [16] SWS [41] MAAS [28]  
(to age 5 years) 
 
MAS 90 [30]  
(to age 7 years) 
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No Wheeze 51.5% 40.3% 55.6% 64.8% 
Transient Early Wheeze 19.9% 45% 23.5% 25.0% 
Late-Onset Wheeze 15.0% 2.2% 5.8% 5.3% 
Persistent Wheeze 13.7% 12.5% 15.1% 4.9% 
 
Table 1B 
Phenotypes Identified TCRS [16] SWS [41] MAAS [28]  
(to age 5 years) 
 
MAS 90 [30]  
(to age 7 years) 
Transient Early Wheeze 41.0% 75.4% 52.9% 71.0%              
Late-Onset Wheeze 30.9% 3.7% 13.1% 15.1% 
Persistent Wheeze 28.2% 20.9% 34.0% 13.9% 
 
 
 
 
Table 2: Proportion of children assigned to each class using data driven analysis for A) the 
whole population, and B) the proportions amongst wheezing children 
Table 2A 
Phenotypes Identified ALSPAC [34] PIAMA [35] MAAS [40] CCCEH [37] SWS [41] 
No Wheeze 61.1% 75.0% 53.3% 47.1% 40.3% 
Transient Early Wheeze 16.5% 16.7% 13.7% 37.5% 17.4% 
Prolonged Early Wheeze 9.3%    27.6% 
Intermediate Onset Wheeze 2.5% 3.1%   6.2% 
Late-Onset Wheeze 4.9% 1.7% 16.7% 7.8% 2.2% 
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Persistent Wheeze 5.8% 3.5%  7.6% 6.4% 
Persistent Troublesome Wheeze   3.2%   
Persistent Controlled Wheeze     13.1%    
 
Table 2B 
Phenotypes Identified ALSPAC [34] PIAMA [35] MAAS [40] CCCEH [37] SWS [41] 
Transient Early Wheeze 42.4% 66.8% 29.3% 70.9% 29.1% 
Prolonged Early Wheeze 23.9%    46.2% 
Intermediate Onset Wheeze 6.4% 12.4%   10.4% 
Late-Onset Wheeze 12.7% 6.8% 35.8% 14.9% 3.68% 
Persistent Wheeze 14.9% 14.0%  14.5% 10.7% 
Persistent Troublesome Wheeze   6.9%   
Persistent Controlled Wheeze     28.1%    
 
Characteristics and Risk Factors Associated with Wheeze Phenotypes 
Understanding the characteristics and risk factors of different wheeze phenotypes can potentially 
elucidate asthma endotypes with distinct causal pathophysiological mechanisms[42]. This in turn can 
facilitate research towards identifying more effective personalised treatment and management 
strategies in accordance with the nature of the endotype. It is acknowledged that this is a highly 
complex area. Wheezing in infants and later development of asthma may be the result of alterations 
of the immune system maturation and acquired modifications of the airway in early life[43,44]. This 
is likely controlled by factors including genetics, epigenetics, environmental exposures and gene-
environment interactions[12]. In this part of the review, we summarise our current understanding of 
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the characteristics of and some risk factors associated with the different wheeze phenotypes 
identified. Table 3 gives an overview of these characteristics and risk factors. 
Early life wheeze (transient and prolonged) 
 Approximately half of all children who wheeze in early life have transient symptoms which do not 
persist in later childhood. Although the original Tucson phenotypes suggested that transient early 
wheeze resolved by age 3 years, this may in part reflect the ages of the children when the data was 
collected (0-3 years and 5-6 years). The data driven approach from ALSPAC suggested that in 
addition to a transient early wheeze (TEW) group (in whom symptoms had largely resolved by 3 
years),  there was a smaller, second group “prolonged early wheeze” (PEW) in whom wheeze 
persisted to ~5 years of age. This group would not have been detected as a separate entity in TCRS 
because of time points of data collection, and may reflect the very large ALSPAC dataset (with data 
collected at 7 time points in seven years). In the PIAMA dataset, the prolonged early wheeze class 
was not identified as a separate entity, but the PIAMA TEW group seemed to reflect a combination 
of the ALSPAC TEW and PEW both in terms of size (accounting for ~70% of children who had 
wheezed, Table 2B) and of time course of prevalence of wheeze. It is of note that the PIAMA cohort 
is significantly smaller in size than ALSPAC. In the SWS compared to TCRS, many more of the SWS 
children had TEW, and fewer had LOW (Table 1B). Interestingly, when the ALSPAC latent classes 
were applied to the SWS, again the combination of TEW and PEW accounted for ~ 70% of the 
children (although in SWS, PEW was more common than TEW, Table 2B).   
It was noted within TCRS that those children with TEW had significantly lower early life lung function 
(measured before any wheeze event, at age 2 months) than all other groups[27], and that this defect 
persisted to age six years.  Within SWS, using the Tucson classification TEW children, early life lung 
function was diminished compared to the never wheezers, but this defect was no longer detectable 
by age 6 years[41]. In contrast, in MAAS TEW was significantly associated with diminished lung 
function at age 5 years, but not at age 3 years[28]. Within ALSPAC there is no data available on lung 
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function in infancy, but when SWS assigned children to the ALSPAC wheeze phenotypes, lung 
function in infancy was diminished in the PEW, and this abnormality in lung function persisted to age 
six years. These data do suggest that early life wheezing is associated with diminished lung function 
prior to the onset of wheeze; however this phenomenon was not seen in a cohort of Australian 
children who had stopped wheezing by age 3 years[33]. It should be noted however that because of 
the technical difficulties in performing lung function in infancy these studies tend to be small.  
Within ALSPAC and PIAMA (where data on infant lung function was not presented), TEW and PEW 
groups had diminished lung function at age 6-8 years (i.e. after wheezing had resolved) compared to 
never wheezers. Airway hyperresponsiveness was either not associated[35,41] or weakly associated 
with membership of this class[34,40]. Allergic sensitisation was not a feature of TEW or PEW groups, 
and neither was eczema or rhinitis associated with these groups.  
Exposure to tobacco smoking has been associated with TEW in all studies where this has been 
investigated [27,36,41]. Exposure to tobacco smoke is also a risk factor for other wheeze phenotypes 
that start early in life (in some but not all studies), but is less consistently associated with late onset 
wheeze. Attending day care has been identified as a risk factor for TEW in three studies. Position in 
sibship and male gender were not consistent across the cohorts [45-47].  Early wheeze is not 
associated with breast feeding, birth weight or BMI, but (like all wheeze phenotypes) is more 
common in those whose mothers have asthma. 
 It is likely that much early wheeze is virally induced [47]. Many children develop symptoms of 
wheeze during early life infection with respiratory syncytial virus (RSV) and observations from 
population based birth cohorts suggest that these children may be at an increased risk of asthma in 
later childhood [48,49]. However, by collecting nasopharyngeal aspirates during and between acute 
respiratory illnesses in a high risk cohort, Jackson et al were able to demonstrate that children who 
wheezed only with RSV during infancy were no more likely to develop asthma by age 6 years than 
those who did not wheeze with RSV (or rhino virus-RV). In contrast, children who wheezed with RV 
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during infancy were at an increased risk of asthma at age 6 years compared to children who did not 
wheeze with RV (or with RSV)[50].  Until molecular mechanisms which underlie these responses are 
elucidated, and genetic predispositions are deciphered, the conflicting results of epidemiological 
studies remain difficult to understand. In the case of RSV, where treatments are available, the true 
effects of RSV on wheezing illness in childhood will not be clarified until the results of randomised, 
placebo-controlled clinical trials which test whether the prevention of RSV lower respiratory illness 
reduces the incidence of subsequent asthma[51]. 
Although  the use of ICS for early wheezing illness does not change the natural history of asthma or 
wheeze in later childhood[52], and the effect of ICS on symptoms in infants with wheezing is minimal 
at best[52,53], many children within transient wheeze classes received inhaled steroids (ICS) in early 
life[35,40].  The transient wheezing group accounts for most of the preschool children receiving 
ICS[40], suggesting over-treatment in this group of children. This is potentially a non-trivial 
misdiagnosis as it has been previously shown that intermittent high dose ICS may affect normal 
growth and development[54].  
 
Persistent Wheeze (troublesome and controlled)  
In all cohorts where this has been investigated, persistent wheeze is characterised by diminished 
lung function by school age [27,28,30,34,41]. Very little infant lung function data is available, and it is 
not clear whether lung function soon after birth is diminished in this group, as results are 
inconsistent between studies[27,41]. In MAAS, children with persistent wheeze fell into two 
separate classes (persistent troublesome wheeze and persistent controlled wheeze[40]); the 
persistent troublesome wheeze group had materially poorer lung function and more reactive 
airways than other groups, including the persistent controlled wheeze group[40]. By using sRaw 
(Specific Airway Resistance) as a measure of lung function it was also possible to see that 
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longitudinal lung function is significantly poorer in the persistent troublesome wheeze compared to 
all other phenotypes, and this effect was seen from age 3 years[40]. Persistent troublesome 
wheezers were also most likely to show bronchial hyperresponsiveness, but again this feature is 
common to other wheeze phenotypes[40].  
More than 50% of children in  the  persistent wheeze class are atopic[47]. However, although this is 
not a feature of transient wheeze, late onset and intermediate onset wheeze phenotypes also 
frequently show this characteristic and so in isolation, this is not a good discriminator of wheeze 
class [27,29,35,36,45]. In a study looking at defining different dimensions of atopy, we found that 
the latent class of multiple early sensitisation was significantly associated with persistent wheeze 
compared to all other wheeze phenotypes[55]. This indicates that not only is asthma and wheezing 
illness a heterogeneous disease with distinct longitudinal profiles in childhood, but also there is also 
a similar underlying latent heterogeneity in atopy[55,56]. Similar to asthma, defining atopy as a 
dichotomous trait may be an oversimplification of this phenotype.   
As with other wheeze phenotypes, maternal history of asthma and gender are significantly 
associated with the risk of persistent wheeze. However, for other associates the data is less 
consistent. Lower socio-economic status was associated with both persistent and early wheeze 
phenotypes in both ALSPAC and SWS, with no significant association with later-onset wheeze 
phenotypes. While SWS found that breastfeeding for less than three months was a significant risk for 
persistent wheeze[41] compared to transient-early wheeze, this association has not been replicated 
in any other study. In the TCRS, this association was found to be confounded by maternal 
asthma.[9,57]  
There was lack of agreement with regards to the association of day-care with persistent wheeze, 
with ALSPAC finding that day-care was associated with an increase in persistent wheeze[36], TCRS 
finding that day-care was protective [27]. Similarly, ALSPAC identified a significant positive 
association between persistent wheeze and number of older siblings[32,36], whereas TCRS found 
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that this was the only wheeze phenotype where the presence of older siblings reduced the risk of 
persistent wheeze[27]. 
Late-onset Wheeze 
Late-onset wheeze is generally characterised as wheeze-onset observed after age three years and 
then persists to later childhood. There is lack of agreement across studies with respect to the 
association of late-onset wheeze with impaired lung function and bronchial hyperresponsiveness. 
ALSPAC[34], PIAMA[35] and MAAS[40] all found that children with late-onset wheeze were 
significantly more likely to have bronchial hyperresponsiveness. However, the Southampton 
Women’s Study (using both the TCRS and ALSPAC definitions) found no significant association of 
late-onset wheeze with bronchial hyperresponsiveness[41]. MAAS and ALSPAC found significant 
association of late-onset wheeze with lung function impairment at age 6[28,34], whereas PIAMA, 
SWS and TCRS found no significant association for either early or late lung function impairment. The 
main characteristic which is consistently associated with late-onset wheeze is sensitisation, both 
before and concurrent with the onset of wheezing events.  
Observational studies have generally found no environmental factors associated with later-onset 
wheeze phenotypes[27,34-36,41]. Two studies identified pre-natal smoking as a risk factor for late-
onset wheeze[27,32]. This result was not replicated in other cohorts[34-36,41]. 
To our knowledge, there is currently no literature available on the history of asthma-related 
symptoms followed up from birth into adulthood. Extensions of current longitudinal birth cohort 
studies into adolescence and adulthood may elucidate whether this late-onset wheeze phenotype 
persists into adulthood or if transient wheezing becomes dormant over a limited period of 
longitudinal observation in childhood and then is retriggered in later life. 
Overall, there are many similarities between the findings of the different studies of wheeze 
phenotypes indicating some reproducibility, whilst acknowledging that there are some clear 
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differences. Further studies of this type will allow future reviewers to draw more firm conclusions as 
to the consistent and replicable phenotypes, which are more likely to indicate discrete endotypes. In 
addition, it is important to consider other features of asthma and to develop more complex models. 
More Complex Models: Dimensions of Respiratory Disease in Childhood 
 
The studies reviewed so far have investigated profiles of recurrent wheeze over time as the main 
marker to establish asthma heterogeneity in childhood. The data-driven approaches described can 
be extended to identify the most relevant symptoms and factors to distinguish between children 
with different phenotypes and disease severity. Syndromes of coexisting symptoms may better 
reflect the underlying pathophysiological processes and persistence of asthma symptoms in 
childhood [58]. Identifying groups of symptoms which coexist for different asthma phenotypes will 
improve diagnosis and identification of patients who respond to treatment. Previous studies have 
looked at understanding the different dimensions of respiratory diseases[58-61]. Although these 
studies are not limited to asthma, they are useful for helping us to distinguish comorbidities of 
different asthma phenotypes. 
 
Defining wheeze phenotypes within a clinical setting 
Two recent studies - the Severe Asthma Research Program (SARP) and the Trousseau Asthma 
Program in Paris (TRAPP) - have defined heterogeneous asthma phenotypes using cross-sectional 
data from a clinical population of asthmatics. Although these studies are cross-sectional in nature 
and therefore do not look at the natural history of asthma development for early identification and 
onset of phenotypes, they are useful for shedding light on the implications of data-driven techniques 
within a clinical setting, and were able to take into account other symptoms of asthma severity 
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besides wheeze. In a study of asthmatic children between ages 6 and 17 years, SARP[62] identified 4 
clusters labelled as 1) late-onset symptomatic asthma (29.8%):  these children had normal lung 
function and less atopy than all other asthmatics; 2) early-onset atopic asthma with normal lung 
function (32.2%);  3) early-onset atopic asthma with mild airflow limitation and comorbidities 
(19.9%) who had the longest asthma duration; and 4) early-onset asthma with advanced airflow 
limitation (18.1%) which differed from 3) in terms of ethnicity (this class had children of mainly 
African descent whereas class 3 was mainly Hispanic), had the highest eNO values, but fewer 
comorbidities compared to class 3).  Using similar statistical techniques, TRAPP[63], a study of 
children between the ages of 6 and 12 years, identified two novel severe asthma phenotypes by 
including inflammatory markers in their cluster analysis, distinguishing between 1) asthma with 
severe exacerbations and multiple allergies (32.7%); 2) severe asthma with bronchial obstruction 
(22.9%) and 3) mild asthma (44.4%). Both studies found poor correlation between the GINA 
guidelines for classifying asthma severity and the asthma phenotypes identified with the respective 
study. Furthermore, the asthma phenotypes identified were better predictors of disease severity 
compared to GINA. This provides evidence of the potential clinical relevance of these data-driven 
approaches to classifying children. 
Strategies for Predicting Asthma Development 
The first three years of life are important in childhood development and the later onset of 
respiratory disease. Of particular interest is the early identification of children who are early 
wheezers and distinguishing between those who will go on to persist in wheezing symptoms from 
those who will grow out of symptoms. This is important for distinguishing between a wheeze 
phenotype which is of a transitory nature in early childhood and wheeze of a more persistent nature 
which may be more in line with current definitions of asthma. Due to the inherent difficulty in 
diagnosing children as “asthmatic” in early life, this may be pivotal in identifying possible early-
intervention strategies for reducing the risk of the later-onset of asthma. The Pollution and Asthma 
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Risk: An Infant Study (PARIS) birth cohort recently identified three distinct phenotypes within the 
first 18 months of life[64]: (1) a mild phenotype (17%), an atopic-severe phenotype (3.2%) and a 
non-atopic severe phenotype (11%), with the remaining 69% of children classified as having no 
recurrent wheeze events. Only with long-term follow up will it become clear whether the wheeze 
classes identified early in life are of prognostic value.   
The Asthma Predictive Index (API) has been used as a tool to predict which children with early-onset 
wheeze will go on to develop persistent symptoms, and to distinguish them from children whose 
wheeze is of a transient nature.  A positive API is given to a child in the first three years of life if they 
have recurrent episodes of wheezing during the previous years in addition to one out of two major 
criteria (physician-diagnosed eczema or parental asthma) or two out of three minor criteria 
(physician-diagnosed allergic rhinitis, wheezing without colds, or peripheral eosinophilia).[65] A 
positive API by age 3 is associated with a 76% chance of active asthma from age 6-13 years, 
compared with <5% chance of active asthma in the school years in those with a negative API at age 
3. Other strategies have been suggested that, although they do not have as good a predictive ability 
as the API, can be used as complementary approaches for identifying persistent wheeze 
endotypes.[66] The PIAMA study suggests 8 clinical parameters for the risk score: male sex, post-
term delivery, parental education and inhaled medication, wheezing frequency, wheeze/dyspnoea 
apart from colds, respiratory infections, and eczema are independent factors to predict subsequent 
asthma.[67]  However, to date, the API has been proposed as the best, most practical strategy for 
predicting children who will develop persistent wheeze.[66]   
Our data suggest that at age 3 years, predictors of subsequent troublesome symptoms amongst 
children with wheezing were large total skin test wheal diameter (≥10mm), history of previous 
exacerbations, diminished lung function and current eczema.[40]   
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Pathophysiological Characteristics and Biomarkers: From Wheeze 
Phenotypes to Asthma Endotypes 
One area of particular interest is identifying biomarkers in early life which can distinguish between 
early-onset wheezers who persist and those with transient symptoms. Early studies investigated 
eosinophilia as a potential biomarker[68-72]. One study showed variations in immune response 
within seemingly homogeneous IgE-mediated asthma phenotypes[73]. Differences in T-cell 
immunity response pattern may be markers of different airway disease endotypes. Non-invasive 
biomarkers, which are more suitable for infants, may be more appropriate for distinguishing 
between different asthma endotypes. Recently, a study has been set-up specifically aimed at making 
reliable asthma diagnosis as early as age two to three years using non-invasive biomarkers such as 
gases and non-volatile inflammatory markers such as cytokines, chemokines and epithelial lining in 
exhaled breath[74]. In future, non-invasive biomarkers are likely to be important in early diagnosis 
and possibly, prevention of asthma[75].  
Fraction of Exhaled Nitric Oxide (FeNO), indicative of Th2-type airway inflammation, has been 
proposed as a potential biomarker for distinguishing endotypes [76-79] in early life due to its non-
invasive nature[76,80-84]. However, FeNO is strongly correlated with atopy[85-88]. Studies have 
found that this biomarker can be used as a biomarker for transient wheeze but not for persistent 
wheeze phenotypes. As early as age one month, an elevated exhaled FeNO was seen in children who 
had recurrent wheeze in the first year of life but not thereafter[77]. FeNO is therefore likely a 
marker of airway inflammation and contemporaneous recurrent wheeze rather than a marker of 
distinct asthma endotypes.  
With the advent of systems biology which combines mathematical computation with proteomics, 
genomics and other biological markers, research in identifying endotypes of asthma[89] has moved 
towards a more integrated approach to understanding interactions of these mechanisms in an 
attempt to identify more definitive asthma endotypes[90]. This has been described in the recent 
literature as the “-omics” approach which uses systems biology by combining potential biomarkers 
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in high dimensional datasets using mathematical modelling techniques to reduce high throughput 
data into a lower dimensional space.  This is a current area of research in computer and 
mathematical science. Such research may provide a more holistic approach for identifying more 
precise diagnostic strategies for understanding different endotypes[91,92]. However, these 
approaches present many challenges. Firstly, such studies need large sample sizes in order to have 
sufficient power in order to identify biological networks associated with different endotypes. 
Although the cost associated with eliciting such high throughput data is currently decreasing, 
funding can still be an issue for such studies. However, the trade-off of that cost would be greater 
efficiency in identifying more targeted treatment strategies. 
Expert Commentary: Clinical Implications of the Asthma Endotype 
One may ask whether wheeze phenotypes identified are clinically relevant and whether these have 
implications for clinical practice. To try to assign children who attend clinic to the wheeze 
phenotypes described in the birth cohorts is neither possible nor desirable. The assumption 
underlying the work reviewed is that asthma is not a single disease, but a group of heterogeneous 
diseases, with different profiles of symptom manifestations in childhood. The rationale of the 
computer-based approaches of pattern recognition reviewed is to better classify symptomatic 
children into groups with common features and ultimately to identify endotypes of asthma. It is 
anticipated that different endotypes will have unique underlying pathophysiological mechanisms 
(and underlying genetic and environmental predictors).  The clinical relevance of this is that different 
“asthmas” may respond differently to different treatments, which will eventually allow us to move 
away from a “one size fits all” approach towards more targeted personalised or stratified therapies 
[46].  This is clinically relevant as one of the main challenges for asthma treatment in children 
remains the lack of understanding as to who will benefit in the long term from currently available 
treatments.[93,94].  However, we are still merely scratching the surface of this problem, and much 
remains to be done in making the leap from defining phenotypes to identifying distinct biological 
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characteristics and mechanisms of endotypes.  Therefore it would be premature to try to apply any 
of this work to current clinical practice. 
Five-year View: The Future of A More Unified Definition of the Asthma 
Endotype 
Since the seminal paper in 1995 from Martinez et al, in which wheeze phenotypes in early life were 
first described, we have made considerable progress in developing computational techniques to 
describe patterns of wheeze and other asthma associated symptoms in early life.  Although the 
literature reviewed shows some disparity in defining phenotypes of early life wheeze, there are 
many common features. However, much work needs to be done to progress to endotypes of 
asthma, with implications for personalized treatments and also preventative strategies. As seen from 
the small number of studies reviewed, few studies have addressed the question of establishing 
asthma phenotypes in a consistent manner. This points towards a need for more longitudinal birth 
cohorts in order to replicate possible genetic and environmental factors associated with different 
asthma phenotypes. 
Computer-assisted reasoning can facilitate research in identifying asthma endotypes and their 
underlying biological mechanisms, capitalising on the wealth of data available from longitudinal birth 
cohorts. Statistical machine learning approaches can take examples of many profiles of the natural 
history of wheeze in order to apply generalisations of the profiles of wheeze on a wider population. 
By applying these techniques, the ‘best’ endotypes across multiple birth cohorts with similar 
characteristics can be identified. Similar to the consortia developed to power genome wide 
association studies, taking account of between cohort heterogeneity, integrating data on the natural 
history of wheeze from different settings would mean obtaining a more complete picture of the 
heterogeneity of asthma on a world-wide population, and thus will help us to make better inference. 
The asthma endotype is a hypothetical construct which has a tangible value in helping us to better 
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understand the natural history of asthma disease-related diseases and therefore identify more 
effective personalised treatment strategies. 
Key Issues 
 Asthma is not a single disease but rather represents an umbrella term used to describe a 
collection of heterogeneous diseases presenting with similar symptoms. 
 Longitudinal birth cohorts have been crucial for conceptualising the natural history of 
wheeze, the most common manifestation of asthma. 
 Both subjective clinician-imposed and objective data-driven approaches have been used to 
capture changing trajectories of wheeze profiles over time in order to identify different 
asthma phenotypes. 
 Computer-based objective data-driven approaches can help achieve a more refined clinician-
based diagnosis by understanding the different types of asthma phenotypes and their 
associated genetic and environmental characteristics. 
 Further work is required to refine the phenotypes currently suggested and identify their 
genetic and environmental associates. 
 By understanding the different phenotypes present in this umbrella term “asthma”, we will 
better understand biological causes, thus facilitating personalised medicine including 
management and prevention strategies. 
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Association With Early Impairment Lung Function (Infancy)        
Cohorts using a Data-driven approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze Persistent Troublesome Wheeze Ref 
ALSPAC Not Done 
 
[34] 
PIAMA Not Done 
 
[35] 
CCCEH Not Done 
 
[37] 
MAAS Not Done 
 
[40] 
Cohorts using an Investigator-Imposed approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze 
   
 
TCRS ↑ No Association No Association 
   
[16] 
ALSPAC Not Done 
 
[32] 
SWS (ALSPAC) No Association ↑↑ No Association ↑ No Association 
 
[41] 
SWS (TCRS) ↑ ↑ No Association      [41] 
Association With Lung Function Impairment by Age 6          
Cohorts using a Data-driven approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze Persistent Troublesome Wheeze Ref 
ALSPAC ↑ ↑↑ ↑ ↑ ↑↑ 
 
[34] 
PIAMA ↑ ↑↑ No Association 
 
No Association 
 
[35] 
CCCEH Not Done 
 
[37] 
MAAS ↑ ↑↑ ↑ 
  
↑↑↑ [40] 
Cohorts using an Investigator-Imposed approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze 
 
 
TCRS ↑ ↑ No Association 
   
[16] 
MAAS ↑ ↑↑ No Association 
   
[28] 
ALSPAC Not Done 
 
[32] 
SWS (ALSPAC) No Association ↑ No Association ↑ No Association 
 
[41] 
SWS (TCRS) No Association ↑ No Association      [41] 
Association With Early Impairment Broncho-hyperresponsiveness        
Cohorts using a Data-driven approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze Persistent Troublesome Wheeze Ref 
ALSPAC ↑ ↑↑ ↑↑ ↑ ↑↑↑ 
 
[34] 
PIAMA No Association ↑↑ ↑↑ 
 
↑↑ 
 
[35] 
CCCEH No published work investigating association of BHR with wheeze phenotypes 
 
[37] 
MAAS ↑ ↑ ↑ 
  
↑↑ [40] 
Cohorts using an Investigator-Imposed approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze 
 
 
TCRS No published work investigating association of BHR with wheeze phenotypes 
 
[16] 
ALSPAC No published work investigating association of BHR with wheeze phenotypes 
 
[32] 
SWS (ALSPAC) No Association No Association No Association No Association No Association 
 
[41] 
SWS (TCRS) No Association No Association No Association      [41] 
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Association With IgE   
 
       
Cohorts using a Data-driven approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze Persistent Troublesome Wheeze Ref 
ALSPAC No published work investigating association of IgE with wheeze phenotypes 
 
[34] 
PIAMA No Association ↑ (only at age 8) ↑↑ (age 4 and 8 years) 
 
↑↑ (age 4 and 8 years) 
 
[35] 
CCCEH Not Done 
 
[37] 
MAAS No Association ↑↑ ↑↑ 
  
↑↑↑ [40] 
Cohorts using an Investigator-Imposed approach to define Wheeze Phenotypes 
  
  
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze 
   
 
TCRS No Association ↑↑  
   
[16] 
ALSPAC No published work investigating association of IgE with wheeze phenotypes 
 
[32] 
SWS No published work investigating association of IgE with wheeze phenotypes   [41] 
Association With Sensitisation (Skin Prick Test)        
Cohorts using a Data-driven approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze Persistent Troublesome Wheeze Ref 
ALSPAC No Association ↑↑ ↑↑ No Association ↑↑↑ 
 
[34] 
PIAMA No published work investigating association of SPT with wheeze phenotypes 
 
[35] 
CCCEH No published work investigating association of SPT with wheeze phenotypes 
  
[37] 
MAAS No Association ↑ ↑ 
  
↑↑ [40] 
Cohorts using an Investigator-Imposed approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze 
 
 
TCRS No Association ↑↑  ↑↑  
   
[16] 
ALSPAC No published work investigating association of SPT with wheeze phenotypes 
  
[32] 
SWS(ALSPAC) No Association ↑↑ (age 3, 6) ↑↑ (age 3 , 6) No Association ↑↑↑ (age 1, 3, 6) 
 
[41] 
SWS (TCRS) ↓ ↑↑ (age 1, 3, 6) ↑↑ (age 3, 6)      [41] 
 
Table 3a: Characteristics of different wheeze phenotypes identified by different longitudinal birth cohorts 
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Association With Smoking            
Cohorts using a Data-driven approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze Persistent Troublesome Wheeze Ref 
ALSPAC ↑ ↑ No Association ↑ No Association 
 
[36] 
PIAMA No published work investigating environmental associates of wheeze phenotypes 
  
[35] 
CCCEH                      Cohort of non-smoking women. No effect of environmental tobacco smoke exposure on any wheeze phenotype [37] 
MAAS ↑↑ ↑↑ No Association 
  
marginal significance (MS ↑) [40] 
Cohorts using an Investigator-Imposed approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze 
   
 
TCRS ↑↑ ↑↑ No Association 
   
[16] 
ALSPAC ↑↑ (prenatal and postnatal) ↑ (Prenatal Only) ↑ (Prenatal Only) 
   
[32] 
SWS ↑↑ ↑↑ No Association       [41] 
Association With Day-care            
Cohorts using a Data-driven approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze Petsistent Troublesome Wheeze  
ALSPAC ↑ ↑ No Association ↑ No Association 
 
[36] 
PIAMA No published work investigating environmental associates of wheeze phenotypes 
 
[35] 
CCCEH No published data 
  
[37] 
MAAS No Association No Association No Association 
  
↓↓ [40] 
Cohorts using an Investigator-Imposed approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze 
   
 
TCRS ↑ ↓↓ No association 
  
[16] 
ALSPAC No published data 
   
[32] 
SWS No published data     [41] 
Association With Gender            
Cohorts using a Data-driven approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze Persistent Troublesome Wheeze  
ALSPAC ↑ ↑ ↑ ↑ ↑ 
 
[36] 
PIAMA No published work investigating association of gender with wheeze phenotypes 
 
[35] 
CCCEH No Association ↑ No Association 
   
[37] 
MAAS ↑↑ ↑↑ ↑ 
  
Marginal Significance ↑  [40] 
Cohorts using an Investigator-Imposed approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze 
   
 
TCRS No Association ↑ ↑ 
   
[16] 
ALSPAC ↑ ↑ ↑ 
   
[32] 
SWS ↑ ↑ Marginal Significance ↑        [41] 
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Association With Older Siblings            
Cohorts using a Data-driven approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze Persistent Troublesome Wheeze Ref 
ALSPAC ↑ ↑ No Association No Association No Association 
 
[36] 
PIAMA No published work investigating association of sibship with wheeze phenotypes 
 
[35] 
CCCEH No published work investigating association of sibship with wheeze phenotypes 
 
[37] 
MAAS No Association ↓↓ No Association 
  
↓ Marginally Significant [40] 
Cohorts using an Investigator-Imposed approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze 
   
 
TCRS ↑ ↓↓ No Association 
   
[16] 
ALSPAC ↑↑ ↑ ↑ 
   
[32] 
SWS No published data  [41] 
Association With BMI/ Weight        
Cohorts using a Data-driven approach to define Wheeze Phenotypes  
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze 
 
 
ALSPAC: Low birth weight 
   
↑ 
 
[36] 
PIAMA No published work investigating association of Weight with wheeze phenotypes 
  
[35] 
CCCEH No published work investigating association of Weight with wheeze phenotypes 
  
[37] 
MAAS No published work investigating association of Weight with wheeze phenotypes 
  
[40] 
Cohorts using an Investigator-Imposed approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze 
   
 
TCRS No published work investigating association of Weight with wheeze phenotypes 
  
[16] 
ALSPAC: Low birth weight No Association No Association ↑ 
   
[32] 
SWS No published work investigating association of Weight with wheeze phenotypes     [41] 
Association With Maternal Asthma        
Cohorts using a Data-driven approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze Prolonged Early Wheeze Intermediate-Onset Wheeze Persistent Controlled Wheeze  
ALSPAC ↑ ↑↑ ↑ ↑ ↑ 
 
[34] 
PIAMA No published work investigating association of Maternal Asthma with wheeze phenotypes 
 
[35] 
CCCEH ↑ ↑↑ ↑ 
   
[37] 
MAAS ↑ ↑↑ ↑↑ 
  
Marginally Significant ↑ [40] 
Cohorts using an Investigator-Imposed approach to define Wheeze Phenotypes 
   
 
 
Transient-Early Wheeze Persistent Wheeze Late-Onset Wheeze 
   
 
TCRS No Association ↑ ↑ 
   
[16] 
ALSPAC ↑ ↑↑ ↑ 
   
[32] 
SWS ↑↑ ↑↑ ↑↑      [41] 
 
Table 3b: Risk factors associated with different wheeze phenotypes identified by different longitudinal birth cohorts 
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